[Lab] first independent cagrilintide purity number i have seen
Right: first independent cagrilintide purity number i have seen. I paid for this one myself, nobody sent me anything, and the receipts are in the comments.
The engineering problem was duration: native amylin is short-acting and aggregation-prone. A long-acting analogue suitable for weekly administration is what makes the combination clinically interesting.
Reading the trial literature on this without misleading yourself.
Separate the monotherapy arms from the combination arms before you do anything else. They report different effect sizes and different tolerability, and almost every summary that circulates blends them.
Then read the tolerability tables rather than the headline. In combination work the interesting question is whether adding a second mechanism adds effect without adding proportionate side effects, and that question is answered in a table nobody quotes.
Finally, note the durations. Comparing a shorter readout here with a longer one from an established compound is not a comparison at all.
The honest state of the evidence on this board, since somebody should write it down.
Published clinical data exists and is genuinely interesting, particularly in combination. Independent purity data from members is thin — a handful of results across the whole site, against hundreds for the older molecules. Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.
What follows practically: buy small if you buy at all, test what you get and post the result, and treat confident rankings against established compounds as the extrapolation they are. The board gets better as the log fills, and right now the log is nearly empty.
That is everything I have. The rest is opinion and I have tried to keep it out.
best — the order this archive was captured in
Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.
the interesting data is the combination, not the monotherapy
nothing here is approved as a standalone product and research material is not for human use
phase 3 data will change most of what gets said here
the co-agonism argument is about complementary mechanisms
Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.
independent purity data on this compound is thin
How many separate lots has anyone here tested?
read the combination arms separately from the monotherapy arms
Went looking for independent results on this and found a handful across the whole site. That is the honest state of the evidence.
The tolerability tables were more informative than the headline numbers, which is usually the case and never how it gets summarised.
Yes. The combination is where the interesting effect sizes are, and the monotherapy arms read very differently.
Correcting myself upthread: I gave the 4-week figure and the paper reports 50 weeks.
Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.
Yes. Anyone reading this board should hold their conclusions loosely until phase 3 reports.
- 1The tolerability tables were more informative than the headline numbers,…6 comments in this branch · started by u/mateusz_adebayo